000285388 001__ 285388
000285388 005__ 20240229155109.0
000285388 0247_ $$2doi$$a10.1186/s12916-023-03152-7
000285388 0247_ $$2pmid$$apmid:37964298
000285388 0247_ $$2altmetric$$aaltmetric:156456837
000285388 037__ $$aDKFZ-2023-02355
000285388 041__ $$aEnglish
000285388 082__ $$a610
000285388 1001_ $$0P:(DE-He78)8224c4651852c416fc2613e1307597c2$$aDecker, Nina Sophia$$b0$$eFirst author$$udkfz
000285388 245__ $$aCirculating oxysterols and prognosis among women with a breast cancer diagnosis: results from the MARIE patient cohort.
000285388 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2023
000285388 3367_ $$2DRIVER$$aarticle
000285388 3367_ $$2DataCite$$aOutput Types/Journal article
000285388 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1700061883_11259
000285388 3367_ $$2BibTeX$$aARTICLE
000285388 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285388 3367_ $$00$$2EndNote$$aJournal Article
000285388 500__ $$a#EA:C020#LA:C020#
000285388 520__ $$aBreast cancer is the most commonly diagnosed cancer in women worldwide, and underlying mechanistic pathways associated with breast cancer-specific and non-breast cancer-related deaths are of importance. Emerging evidence suggests a role of oxysterols, derivates of cholesterol, in multiple chronic diseases including breast cancer and coronary artery diseases. However, associations between oxysterols and survival have been minimally studied in women diagnosed with breast cancer. In this large breast cancer patient cohort, we evaluated associations between a panel of circulating oxysterols and mortality and recurrence outcomes.Concentrations of 13 circulating oxysterols representing different pathways of cholesterol metabolism were quantified using liquid-chromatography mass-spectrometry. Associations between baseline levels of oxysterols and cause-specific mortality outcomes and recurrence following a breast cancer diagnosis were assessed in 2282 women from the MARIE study over a median follow-up time of 11 years. We calculated hazard ratios (HR) and 95% confidence intervals (CI) using multivariable Cox proportional hazard models and competing risks models.We observed no associations for circulating oxysterols and breast cancer-specific outcomes. Higher levels of six oxysterols were associated with an increased risk of cardiovascular disease death, including 24S-hydroxycholesterol (alternative bile acid pathway, HRlog2 = 1.73 (1.02, 2.93)), lanosterol (cholesterol biosynthesis pathway, HRlog2 = 1.95 (1.34, 2.83)), 7-ketocholesterol (HRlog2 = 1.26 (1.03, 1.55)), 5α,6α-epoxycholesterol (HRlog2 = 1.34 (1.02-1.77)), and 5a,6β-dihydroxycholestanol (HRlog2 = 1.34 (1.03, 1.76)). After adjusting for multiple comparisons, none of the associations were statistically significant.We provide first evidence on a range of circulating oxysterols and mortality following a breast cancer diagnosis, contributing to a better understanding of associations between different pathways of cholesterol metabolism and prognosis in women with a breast cancer diagnosis. The findings of this study suggest circulating oxysterols may be associated with cardiovascular mortality among women diagnosed with breast cancer. Further studies are needed to evaluate these oxysterols as potential markers of risk for cardiovascular mortality among women with a breast cancer diagnosis as well as their clinical potential.
000285388 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000285388 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285388 650_7 $$2Other$$aBreast cancer
000285388 650_7 $$2Other$$aCancer death
000285388 650_7 $$2Other$$aCardiovascular death
000285388 650_7 $$2Other$$aCholesterol metabolism
000285388 650_7 $$2Other$$aCohort study
000285388 650_7 $$2Other$$aMolecular epidemiology
000285388 650_7 $$2Other$$aOxysterols
000285388 650_7 $$2Other$$aSurvival
000285388 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b1$$udkfz
000285388 7001_ $$aVey, Johannes A$$b2
000285388 7001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b3$$udkfz
000285388 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b4$$udkfz
000285388 7001_ $$aObi, Nadia$$b5
000285388 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b6$$udkfz
000285388 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$udkfz
000285388 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b8$$eLast author$$udkfz
000285388 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-023-03152-7$$gVol. 21, no. 1, p. 438$$n1$$p438$$tBMC medicine$$v21$$x1741-7015$$y2023
000285388 909CO $$ooai:inrepo02.dkfz.de:285388$$pVDB
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8224c4651852c416fc2613e1307597c2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000285388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000285388 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000285388 9141_ $$y2023
000285388 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2022$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:07:15Z
000285388 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:07:15Z
000285388 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:07:15Z
000285388 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2022$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000285388 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000285388 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000285388 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000285388 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000285388 980__ $$ajournal
000285388 980__ $$aVDB
000285388 980__ $$aI:(DE-He78)C020-20160331
000285388 980__ $$aUNRESTRICTED